Pharmacological bases for the use of dopamine and related drugs in the treatment of congestive heart failure.
The purpose of this paper is to review the pharmacological background of the use of dopamine (DA), DA agonists, and DA prodrugs in the treatment of congestive heart failure (CHF). Studies leading to the use of DA and methods utilized to investigate new DA agonists are reviewed. Finally, preclinical and clinical data of DA agonists and prodrugs are evaluated to estimate current and future roles of DA, DA agonists, and DA prodrugs in the treatment of congestive heart failure.
Goldberg
L I
LI
Department of Pharmacological Sciences and Medicine, University of Chicago, Illinois.
D000818:Animals; D004285:Dogs; D004298:Dopamine / Q000494:pharmacology* / Q000627:therapeutic use; D015259:Dopamine Agents / Q000494:pharmacology / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D009200:Myocardial Contraction / Q000187:drug effects; D011355:Prodrugs / Q000494:pharmacology / Q000627:therapeutic use; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D011954:Receptors, Dopamine / Q000187:drug effects
D015259:Dopamine Agents; D011355:Prodrugs; D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D011954:Receptors, Dopamine; D004298:Dopamine